A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.

被引：1
|
作者：
Shitara, Kohei
Yonesaka, Kimio
Denda, Tadamichi
Yamazaki, Kentaro
Moriwaki, Toshikazu
Tsuda, Masahiro
Takano, Toshimi
Okuda, Hiroyuki
Nishina, Tomohiro
Sakai, Kazuko
Nishio, Kazuto
Tokunaga, Shoji
Yamanaka, Takeharu
Boku, Narikazu
Hyodo, Ichinosuke
Muro, Kei
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3567
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
    Shimoyama, Rai
    Kimura, Tetsuo
    Takaoka, Toshi
    Sakamoto, Kazuki
    Kawamoto, Shunji
    Yoshizaki, Koji
    Negoro, Yuji
    Goda, Fuminori
    Tsuji, Akihito
    Nakayama, Tsuyoshi
    Miyamoto, Hiroshi
    Takayama, Tetsuji
    Niitsu, Yoshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [42] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Watanabe, Jun
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Mori, Ikuo
    Yamanaka, Kazunori
    Hihara, Masamitsu
    Soeda, Junpei
    Yamanaka, Takeharu
    Akagi, Kiwamu
    Ochiai, Atsushi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [43] Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST)
    Price, T. J.
    Sobrero, A. F.
    Wilson, G.
    Van Cutsem, E.
    Aleknaviciene, B.
    Zaniboni, A.
    Hartmann, J. T.
    Tian, Y.
    Gansert, J. L.
    Peeters, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Efficacy outcomes by severity of skin toxicity from ASPECCT: Randomized phase 3 study of panitumumab (pmab) versus cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC)
    Price, T.
    Kim, T. W.
    Li, J.
    Cascinu, S.
    Ruff, P.
    Suresh, A. S.
    Thomas, A.
    Tjulandin, S.
    Guan, X.
    Hoang, T.
    Hei, Y. J.
    Peeters, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S366 - S366
  • [45] Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC)
    Price, Timothy Jay
    Peeters, Marc
    Kim, Tae Won
    Li, Jin
    Cascinu, Stefano
    Ruff, Paul
    Suresh, Attili Venkatasatya
    Thomas, Anne L.
    Tjulandin, Sergei
    Zhang, Kathy
    Sidhu, Roger
    Murugappan, Swaminathan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Predictive value of primary tumor location: Results from randomized phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)
    Tamura, T.
    Sakai, D.
    Sugimoto, N.
    Tokunaga, S.
    Tsuji, A.
    Ishida, H.
    Otsu, S.
    Moriwaki, T.
    Satake, H.
    Uchino, K.
    Matsumoto, S.
    Baba, E.
    Sato, M.
    Taniguchi, H.
    Kishimoto, J.
    Boku, N.
    Hyodo, I.
    Muro, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Trial in progress: A phase II study of second-line FOLFIRI plus panitumumab after first-line FOLFOX plus panitumumab for RAS wild-type colorectal cancer with evaluation of circulating tumor DNA.
    Maeda, Hiromichi
    Nagata, Naoki
    Nagasaka, Takeshi
    Oba, Koji
    Mishima, Hideyuki
    Kato, Takeshi
    Yoshida, Kazuhiro
    Muro, Kei
    Sakamoto, Junichi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [48] PANITUMUMAB PLUS FOLFOX4 OR PANITUMUMAB PLUS FOLFIRI IN SUBJECTS WITH WILD-TYPE KRAS (EXON 2) COLORECTAL CANCER AND MULTIPLE OR UNRESECTABLE LIVER-LIMITED METASTASES: DATA FROM THE RANDOMIZED, PHASE II PLANET STUDY
    Abad, A.
    Massuti, B.
    Gravalos, C.
    Escudero, P.
    Guillen-Ponce, C.
    Layos, L.
    Gomez, M. A.
    Safont, M. J.
    Gallego, J.
    Sastre, J.
    Pericay, C.
    Duenas, R.
    Lopez-Lopez, C.
    Losa, F.
    Valladares, M.
    Gonzalez-Flores, E.
    Yuste, A.
    Robles, L.
    Saenz, A.
    Cano, T.
    Carrato, A.
    Aranda, E.
    ANNALS OF ONCOLOGY, 2014, 25 : 8 - 8
  • [49] A RANDOMIZED, PHASE IB/II TRIAL OF RILOTUMUMAB (AMG 102; RIL) OR GANITUMAB (AMG 479; GAN) WITH PANITUMUMAB (PMAB) VS PMAB ALONE IN PATIENTS WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (MCRC): PRIMARY AND BIOMARKER ANALYSES
    Tebbutt, Niall C.
    Van Cutsem, Eric
    Eng, Cathy
    Nowara, Elzbieta
    Wieboda-Sadle, Anna
    Mitchell, Edith
    Davidenko, Irina
    Oliner, Kelly S.
    Chen, Lisa
    Huang, Jing
    Loh, Elwyn
    Gasal, Eduard
    Tabernero, Josep
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 311 - 311
  • [50] Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)
    De Stefano, A.
    Nasti, G.
    Febbraro, A.
    Rosati, G.
    Giuliani, F.
    Santini, D.
    Aprile, G.
    Scartozzi, M.
    Silvestris, F.
    Luppi, G.
    Lolli, I.
    Mastroianni, C.
    Leo, S.
    Montesarchio, V.
    Gridelli, C.
    Pozzo, C.
    Sperti, E.
    Giannarelli, D.
    Budillon, A.
    Avallone, A.
    ANNALS OF ONCOLOGY, 2018, 29
12345